{"id":74708,"date":"2020-09-28T09:55:35","date_gmt":"2020-09-28T07:55:35","guid":{"rendered":"https:\/\/www.cfmot.de\/verrucarin-a-in-cancer-therapy\/"},"modified":"2020-09-28T10:05:37","modified_gmt":"2020-09-28T08:05:37","slug":"verrucarin-a-in-cancer-therapy","status":"publish","type":"post","link":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/","title":{"rendered":"Verrucarin A in cancer therapy"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"74708\" class=\"elementor elementor-74708 elementor-74694\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-c3c0b0e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"c3c0b0e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c2fc3b4\" data-id=\"c2fc3b4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-892e9fa elementor-widget elementor-widget-text-editor\" data-id=\"892e9fa\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Pancreatic cancer (ductal pancreatic adenocarcinoma \/ PDA) is one of the most difficult cancers to treat. Common chemotherapeutic agents often only bring about a short-term improvement in symptoms and, unfortunately, experience has shown that they have little effect on the patient&#8217;s recovery. New types of therapy are urgently needed here.\u00a0<\/p>\n<p>This is where Verrucarin A comes into play. Trichothecenes are mycotoxins that inhibit protein synthesis and cause ribotoxic stress reactions in mammalian cells. Verrucarin A (VC-A) is a type D macrocyclic mycotoxin. It inhibits cell proliferation and causes apoptosis in breast cancer cells.\u00a0<\/p>\n<h3 id=\"tw-target-text\" class=\"tw-data-text tw-text-large XcVN5d tw-ta\" dir=\"ltr\" data-placeholder=\"\u00dcbersetzung\"><span lang=\"en\">Verrucarin A and its potent anti-tumor activity<\/span><\/h3>\n<p>Verrucarin A also affects PDA cells. Strong anti-tumor activity is observed here. Verrucarin A strongly inhibits proliferation and blocks cells in the S phase. Blocking the progression of the cell cycle goes hand in hand with the inhibition of the cell cycle regulatory proteins cyclin D1, cyclin E, cyclin-dependent kinases (cdks) cdk2, cdk4 and cdk inhibitor WAF1 \/ 21.\u00a0<\/p>\n<p>Verrucarin A causes apoptosis in PDA cells, as shown by the increased annexin V-FITC binding, cleavage of poly (ADP-ribose) polymerase 1 (PARP-1) and procaspases-3, -8 and -9. VC-A also causes mitochondrial depolarization and release of cytochrome c and inhibits proteins of the Bcl-2 family that regulate apoptosis (Bcl-2, Bcl-xL, Bax and Bad).\u00a0<\/p>\n<h3 id=\"tw-target-text\" class=\"tw-data-text tw-text-large XcVN5d tw-ta\" dir=\"ltr\" data-placeholder=\"\u00dcbersetzung\"><span lang=\"en\">Verrucarin A reduces apoptosis inhibitors<\/span><\/h3>\n<p>Verrucarin A also reduces the apoptosis inhibitors survivin and c-IAP-2. It downregulates the expression of prosurvival phospho-Akt (p-Akt), core factor \u03baB (NF-\u03baB) (p65) and mammalian target of rapamycin (p-mTOR) signaling proteins and their downstream mediators.\u00a0<\/p>\n<p>In conclusion, it can be said: The research results show a strong antiproliferative and apoptosis-inducing activity of verrucarin A for PDA cells due to the arrest of the cell cycle and inhibition of the prosurvival (anti-apoptotic) AKT \/ NF-\u03baB \/ mTOR signal.\u00a0<\/p>\n<p><strong>We offer Verrucarin A in bulk quantities and look forward to your inquiry \u2013 whether by phone or directly via our <a href=\"https:\/\/www.cfmot.de\/en\/produkt\/verrucarin-a-2\/\">contact form<\/a>.\u00a0<\/strong><\/p>\n<p>Photo: Creative commons &#8211; Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0)<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Pancreatic cancer (ductal pancreatic adenocarcinoma \/ PDA) is one of the most difficult cancers to treat. Common chemotherapeutic agents often only bring about a short-term improvement in symptoms and, unfortunately, experience has shown that they have little effect on the patient&#8217;s recovery. New types of therapy are urgently needed here.\u00a0 This is where Verrucarin A [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":74696,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[48,133,139],"tags":[],"class_list":["post-74708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en-2","category-news-en","category-pharmaceutical-products"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verrucarin A in cancer therapy - Cfm Oskar Tropitzsch GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verrucarin A in cancer therapy - Cfm Oskar Tropitzsch GmbH\" \/>\n<meta property=\"og:description\" content=\"Pancreatic cancer (ductal pancreatic adenocarcinoma \/ PDA) is one of the most difficult cancers to treat. Common chemotherapeutic agents often only bring about a short-term improvement in symptoms and, unfortunately, experience has shown that they have little effect on the patient&#8217;s recovery. New types of therapy are urgently needed here.\u00a0 This is where Verrucarin A [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Cfm Oskar Tropitzsch GmbH\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-28T07:55:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-09-28T08:05:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/09\/pankreaskopf-karzinom_20200807_1580613626.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"849\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karin Bayer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karin Bayer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/\"},\"author\":{\"name\":\"Karin Bayer\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/0192b39a358835d45c94562d47c033c7\"},\"headline\":\"Verrucarin A in cancer therapy\",\"datePublished\":\"2020-09-28T07:55:35+00:00\",\"dateModified\":\"2020-09-28T08:05:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/\"},\"wordCount\":325,\"image\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/pankreaskopf-karzinom_20200807_1580613626.jpg\",\"articleSection\":[\"Blog\",\"News\",\"Pharmaceutical Products\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/\",\"name\":\"Verrucarin A in cancer therapy - Cfm Oskar Tropitzsch GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/pankreaskopf-karzinom_20200807_1580613626.jpg\",\"datePublished\":\"2020-09-28T07:55:35+00:00\",\"dateModified\":\"2020-09-28T08:05:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/0192b39a358835d45c94562d47c033c7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/pankreaskopf-karzinom_20200807_1580613626.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cfmot.de\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/pankreaskopf-karzinom_20200807_1580613626.jpg\",\"width\":849,\"height\":600,\"caption\":\"Kostenlose Illustration Bauchspeicheldr\u00fcsenkrebs (Pankreaskopfkarzinoms). In der Abbildung ist ein Tumor von der Bauchspeicheldr\u00fcse ausgehend in den Zw\u00f6lffingerdarm eingewachsen.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/verrucarin-a-in-cancer-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verrucarin A in cancer therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/\",\"name\":\"Cfm Oskar Tropitzsch GmbH\",\"description\":\"Chemikalien, Feinchemikalien, Metallverbindungen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/#\\\/schema\\\/person\\\/0192b39a358835d45c94562d47c033c7\",\"name\":\"Karin Bayer\",\"url\":\"https:\\\/\\\/www.cfmot.de\\\/en\\\/author\\\/karin-bayer\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verrucarin A in cancer therapy - Cfm Oskar Tropitzsch GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Verrucarin A in cancer therapy - Cfm Oskar Tropitzsch GmbH","og_description":"Pancreatic cancer (ductal pancreatic adenocarcinoma \/ PDA) is one of the most difficult cancers to treat. Common chemotherapeutic agents often only bring about a short-term improvement in symptoms and, unfortunately, experience has shown that they have little effect on the patient&#8217;s recovery. New types of therapy are urgently needed here.\u00a0 This is where Verrucarin A [&hellip;]","og_url":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/","og_site_name":"Cfm Oskar Tropitzsch GmbH","article_published_time":"2020-09-28T07:55:35+00:00","article_modified_time":"2020-09-28T08:05:37+00:00","og_image":[{"width":849,"height":600,"url":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/09\/pankreaskopf-karzinom_20200807_1580613626.jpg","type":"image\/jpeg"}],"author":"Karin Bayer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Karin Bayer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/#article","isPartOf":{"@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/"},"author":{"name":"Karin Bayer","@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/0192b39a358835d45c94562d47c033c7"},"headline":"Verrucarin A in cancer therapy","datePublished":"2020-09-28T07:55:35+00:00","dateModified":"2020-09-28T08:05:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/"},"wordCount":325,"image":{"@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/09\/pankreaskopf-karzinom_20200807_1580613626.jpg","articleSection":["Blog","News","Pharmaceutical Products"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/","url":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/","name":"Verrucarin A in cancer therapy - Cfm Oskar Tropitzsch GmbH","isPartOf":{"@id":"https:\/\/www.cfmot.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/09\/pankreaskopf-karzinom_20200807_1580613626.jpg","datePublished":"2020-09-28T07:55:35+00:00","dateModified":"2020-09-28T08:05:37+00:00","author":{"@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/0192b39a358835d45c94562d47c033c7"},"breadcrumb":{"@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/#primaryimage","url":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/09\/pankreaskopf-karzinom_20200807_1580613626.jpg","contentUrl":"https:\/\/www.cfmot.de\/wp-content\/uploads\/2020\/09\/pankreaskopf-karzinom_20200807_1580613626.jpg","width":849,"height":600,"caption":"Kostenlose Illustration Bauchspeicheldr\u00fcsenkrebs (Pankreaskopfkarzinoms). In der Abbildung ist ein Tumor von der Bauchspeicheldr\u00fcse ausgehend in den Zw\u00f6lffingerdarm eingewachsen."},{"@type":"BreadcrumbList","@id":"https:\/\/www.cfmot.de\/en\/verrucarin-a-in-cancer-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cfmot.de\/en\/"},{"@type":"ListItem","position":2,"name":"Verrucarin A in cancer therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.cfmot.de\/en\/#website","url":"https:\/\/www.cfmot.de\/en\/","name":"Cfm Oskar Tropitzsch GmbH","description":"Chemikalien, Feinchemikalien, Metallverbindungen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cfmot.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.cfmot.de\/en\/#\/schema\/person\/0192b39a358835d45c94562d47c033c7","name":"Karin Bayer","url":"https:\/\/www.cfmot.de\/en\/author\/karin-bayer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/74708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/comments?post=74708"}],"version-history":[{"count":3,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/74708\/revisions"}],"predecessor-version":[{"id":74711,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/posts\/74708\/revisions\/74711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/media\/74696"}],"wp:attachment":[{"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/media?parent=74708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/categories?post=74708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cfmot.de\/en\/wp-json\/wp\/v2\/tags?post=74708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}